Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
Beijing Biotech
Chinese PLA General Hospital
National Institutes of Health Clinical Center (CC)
AvenCell Therapeutics, Inc.
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
Allogene Therapeutics
National Institutes of Health Clinical Center (CC)
Medical University of South Carolina
Lyell Immunopharma, Inc.
Intima Bioscience, Inc.
Intima Bioscience, Inc.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Essen Biotech
Fred Hutchinson Cancer Center
Dana-Farber Cancer Institute
Washington University School of Medicine
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
TCRCure Biopharma Ltd.
Xinqiao Hospital of Chongqing
National Institutes of Health Clinical Center (CC)
Masonic Cancer Center, University of Minnesota
M.D. Anderson Cancer Center
Astellas Pharma Inc
National Institutes of Health Clinical Center (CC)
Changhai Hospital
M.D. Anderson Cancer Center
Fred Hutchinson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
ARCE Therapeutics, Inc.
H. Lee Moffitt Cancer Center and Research Institute
National Institutes of Health Clinical Center (CC)
Fred Hutchinson Cancer Center
UNC Lineberger Comprehensive Cancer Center
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
Gilead Sciences
National Institutes of Health Clinical Center (CC)
National University Hospital, Singapore
Chinese PLA General Hospital